NIST shows cross-platform TBMNK standardisation across 42 cytometers and 21 sites
Summary
A NIST-coordinated interlaboratory study standardized a human TBMNK assay across 42 cytometers from 7 manufacturers at 21 sites, reporting cell counts and fluorescence in quantitative, traceable units and producing an AI-ready reference dataset.
The evidence
The NIST Flow Cytometry Standards Consortium coordinated a TBMNK interlaboratory study using common samples, control and assay reagents, and four SOPs across 42 cytometers from 7 manufacturers at 21 sites.
Results were reported as cells per microlitre for counts and Equivalent Reference Fluorophore units for marker expression, providing a common quantitative scale across platforms.
CFCM explainer — standardisation before AI
Common samples + SOPs → instrument calibration → quantitative units → harmonised analysis → reference dataset for AI/ML work.
Source/credit: CFCM explainer based on NIST and the open-access Frontiers in Immunology publication, published 28 September 2026.
The study supports the idea that AI transferability starts with measurement comparability rather than model architecture alone. It does not show that any particular clinical AI model is externally validated. The authors identify automated sample preparation as a next step for reducing remaining assay uncertainty.
AI Evidence Tracker: instrument harmonisation — strong; fluorescence calibration — strong, ERF-based; metadata completeness — substantial study/SOP metadata; external-site validation — strong for the assay standardisation framework, not for a diagnostic AI model; domain-shift evidence — directly addresses multi-platform variation; OOD/failure handling — not a focus of this study.
Interpretation and limitations
What this means for laboratories
Source Date
September 28, 2026
Event date
September 28, 2026
Commercial Regulatory Status
Published research and standardisation framework; not a regulatory standard and not an IVD authorization.
Primary source
Read the source →An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →CFCM WEEKLY · EVERY SUNDAY
The science behind the signal, in your inbox.
Get evidence-led clinical flow cytometry news, original conference posters, figures from published papers, practical learning pills, an advanced quiz and the story of one CD marker each week. Free. No spam.
Get CFCM Weekly →Complete the form and confirm the email we send you. Unsubscribe any time. Privacy policy.